Salacir Tablets USP 500 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Salacir Tablets USP 500 mg | Manufacturer
Product image for Salacir Tablets USP 500 mg Manufacturer; contract manufacturing, oem & quality control.
Product Information
| Generic Name | Salacir |
|---|---|
| Manufacturer | Healthy Life Pharma Pvt. Ltd. |
| HSN Code | 30049099 |
| Pharmacopoeia | USP |
| Product Type | Tablet |
| Category | Anti-inflammatory drugs – 5-ASA |
| Subcategory | 5-ASA |
| Active Ingredient | Salacir |
| Strength | 500 mg |
| Dosage Form | Tablet |
| Pack Size | 10 x 10 Tablets / Box (Alu-Alu / Blister) |
| Route of Administration | Oral |
| Prescription Required | Yes |
| Therapeutic Category | Anti-inflammatory drugs – 5-ASA |
Medicine Details & Safety
| Short Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Salacir Tablets USP 500 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Approved Uses / Indications | 1. Relief of pain and functional stiffness in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. 2. Management of acute painful musculoskeletal disorders, tenosynovitis, lumbago, dentalgia, and post-traumatic injury. | ||||||||||||||||||||||||
| Full Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Salacir Tablets USP 500 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. Product technical specifications
Product technical specifications
Manufacturing capabilities and infrastructureFor Salacir Tablets USP 500 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.Quality control and assuranceRequest the approved finished-product specification for Salacir Tablets USP 500 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.Primary and secondary packagingThe catalogue pack for Salacir Tablets USP 500 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.Contract manufacturing and private labelSubmit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution. | ||||||||||||||||||||||||
| Dosage Instructions | Administer orally with a full glass of water, preferably with or immediately following meals to minimize gastric irritation. Do not exceed the maximum prescribed daily dosage. Use the lowest effective dose for the shortest treatment duration necessary. | ||||||||||||||||||||||||
| Side Effects | Common: Epigastric discomfort, dyspepsia, heartburn, nausea, abdominal pain. Uncommon: Dizziness, headache, mild diarrhea, flatulence, constipation. Rare: Peptic ulceration, gastrointestinal hemorrhage, elevated transaminases, hypersensitivity rash. | ||||||||||||||||||||||||
| Warnings and Precautions | Gastrointestinal Safety: Long-term administration can lead to gastric mucosal erosion, ulceration, or bleeding. Cardiovascular & Renal Caution: Use with caution in patients with preexisting hypertension, congestive heart failure, or renal compromise. Monitor renal parameters periodically. | ||||||||||||||||||||||||
| Contraindications | 1. Known hypersensitivity to Salacir, aspirin, or other NSAIDs. 2. Active peptic ulcer disease, gastrointestinal hemorrhage, or history of perforation. 3. Severe heart failure (NYHA Class III-IV), severe hepatic cirrhosis, or advanced renal failure. 4. Third trimester of pregnancy. | ||||||||||||||||||||||||
| Drug Interactions | 1. Anticoagulants & Antiplatelets (Warfarin, Clopidogrel): Increased risk of serious GI bleeding. 2. ACE Inhibitors, ARBs & Diuretics: Attenuated antihypertensive efficacy and increased nephrotoxicity risk. 3. Methotrexate & Lithium: Reduced renal clearance causing elevated serum concentrations and toxicity. |
Frequently Asked Questions
| Question | Answer |
|---|---|
| Can I request third-party manufacturing for Salacir Tablets USP 500 mg? | Submit your brand, quantity and packaging requirements for manufacturing feasibility review. |
| Which pharmacopoeial standard applies for Salacir Tablets USP 500 mg? | The source specification is USP; confirm the required standard before contracting. |
| What quality tests are applicable for Salacir Tablets USP 500 mg? | Request the approved finished-product specification and batch testing plan. |
| Can packaging be customized for Salacir Tablets USP 500 mg? | Submit artwork and pack requirements for technical and regulatory review. |
| How do I request a manufacturing quotation for Salacir Tablets USP 500 mg? | Provide forecast volume, target market, strength and packaging requirements. |
Related Products
Latest Posts
✚
WHO GMP certfied Glibenclamide Metformin SR TabletsRead article →✚
WHO GMP certfied Frusemide Tablets ManufacturerRead article →✚
Folic Acid Niacinamide Tablets ManufacturerRead article →✚
WHO GMP certfied Folic Acid Tablets ManufacturerRead article →✚
WHO GMP certfied Fluconazole Tablets ManufacturerRead article →✚
WHO GMP certfied Ferrous Sulphate with folic acid TabletsRead article →✚
WHO GMP certfied iron with folic acid Tablets ManufacturerRead article →✚
WHO GMP certfied Ferrous Sulphate Tablets ManufacturerRead article →